SU9516 - CDK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESU9516Cat. No.: HY-18629CAS No.: 377090-84-1分式: CHNO分量: 241.25作靶點: CDK; Autophagy作通路: Cell Cycle/DNA Damage; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 100 mg/mL (414.51 mM)H2

2、O : 40% PEG300 5% Tween-80 45% salineSolubility: 3.25 mg/mL (13.47 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 3.25 mg/mL (13.47 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 SU9516種有效的 CDK2 抑制劑，IC50 值為 22 nM，同時對 CDK1 和 CDK4 也有抑制作，IC

3、50 值分別為40 和 200 nM。IC50 & Target CDK2 CDK1 CDK4 PDGFr22 nM (IC50) 40 nM (IC50) 200 nM (IC50) 18000 nM (IC50)體外研究 SU9516 shows slight activities against PKC, p38, PDGFr and EGFR, with IC50 of 10, 10, 18, and 100 M. SU9516 (5 M) decreases cdk2-specific Phosphorylation of pRB and inhibits cell cycle pr

4、ogression inRKO cells. SU9516 (5 M) also induces apoptosis in RKO and SW480 Cells 1. SU9516 (5 M) results inenhanced pRb/E2F complex formation in HT-29 cells. SU9516 enhances presence of E2F species inmultiprotein complexes 2. SU9516 (5 M) rapidly induces cytochrome crelease, Bax mitochondrialtransl

5、ocation, and apoptosis in association with pronounced down-regulation of the antiapoptotic protein Mcl-1. SU9516 causes down-regulation of Mcl-1 mRNA levels in human leukemia cells. Furthermore, SU9516treatment results in a marked increase in reactive oxygen species production 3.PROTOCOLKinase Assay

6、 1 Kinase assays are performed in 96-well polypropylene plates. Each reaction contains 2 g of histone H1 at afinal concentration of 10 M -33PATP (0.2 Ci/well), 10 mM MgCl2,1mM DTT, 0.01% Triton X-100, and10% glycerol in a 40 L volume. The reaction is initiated with the addition of 20 L enzyme (6 ng

7、cdk2/wellresulting in a final concentration of 1.6 nM), which is previously diluted 1:50-1:200 in the same buffer, andallowed to proceed for 1 h at room temperature. Reaction is stopped by the addition of 0.01 mL 10%phosphoric acid, and 25 L of reaction mixture is transferred to P30 phosphocellulose

8、 filter mat paper. Thefilter mat is washed three times with 1.0% phosphoric acid, air dried, and then counted for radioactivity in aliquid scintillation counter.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 RKO cells and SW480 cells are s

9、eeded in replicates (n = 6) in 96-well plates at 1104 cells/well and allowedto attach overnight. SU9516 is added in concentrations from 0.05 M to 50.00 M for 24 h, the cells are thenwashed twice with PBS, and cells are replenished with complete media. The cells are fixed at 0, 4, and 7days post-drug

10、 removal and assayed for protein levels using a modified SRB cytotoxicity assay. The cells arefixed in 10% trichloroacetic acid for 1 h, washed in distilled H2O, and stained in 0.4% SRB/acetic acid for 30min. The cells are then washed in 0.1% acetic acid, solubilized in 10 mM Tris (pH 9), and analyz

11、ed on a Bio-Rad 360 microplate reader at 595 nm. All experiments are repeated at least three times.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 J Exp Clin Cancer Res. 2018 Feb 27;37(1):40.See more customer validations on HYPERLINK / www.M

12、edChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug15;61(16):6170-7.2. Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high

13、 molecular weight E2F complexes in humancolon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64(7):1091-100.3. Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-1-(3H-imidazol-4-yl)-meth-(Z)-ylidene-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. MolPharmacol. 2006 Aug;70(2):645-55.Mc